- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 12, 2022
Product Development
CRISPR Therapeutics advances CAR T modality in T cell cancers
CRISPR-edited CAR T CTX130 generates responses in challenging T cell lymphoma indications
BioCentury | Feb 16, 2022
Product Development
Legend clinical hold raises questions about CAR Ts for T cell cancers
A drop in CD4+ T cells triggers clinical hold for Legend CAR T trial
BioCentury | Dec 11, 2021
Discovery & Translation
New targets at ASH hint at an emerging T cell cancer focus
BioCentury’s ASH21 analysis identifies 22 new targets spanning seven mechanistic categories
Items per page:
1 - 3 of 3